Search Results
Ovarian Cancer: Maintenance Following Frontline Bevacizumab
Frontline Bevacizumab Strategies in Ovarian Cancer
Biomarker-Driven Frontline Ovarian Cancer Treatment
Dr. Arend on FDA Approval of Frontline Bevacizumab in Ovarian Cancer
PARP + Maintenance Bevacizumab in Ovarian Cancer
Frontline VEGF Inhibition in Advanced Ovarian Cancer
Updates in Ovarian Cancer: Frontline Maintenance
Dr. Herzog on the FDA Approval of Olaparib/Bevacizumab as Frontline Maintenance in Ovarian Cancer
The Impact of PAOLA-1 on Frontline Treatment of Ovarian Cancer
GOG-0218: Frontline Bevacizumab in Ovarian Cancer
Maintenance Therapy: PARP Inhibitor or Bevacizumab
Approaching Frontline Therapy Options for Ovarian Cancer
